Filing Details

Accession Number:
0001209191-17-044940
Form Type:
4
Zero Holdings:
No
Publication Time:
2017-07-12 17:55:56
Reporting Period:
2017-07-10
Filing Date:
2017-07-12
Accepted Time:
2017-07-12 17:55:56
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1377121 Protagonist Therapeutics Inc PTGX Pharmaceutical Preparations (2834) 980505495
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1675881 Y David Liu C/O Protagonist Therapeutics, Inc.
7707 Gateway Blvd., Suite 140
Newark CA 94560-1160
Chief Scientific Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2017-07-10 3,500 $1.89 5,500 No 4 M Direct
Common Stock Disposition 2017-07-10 3,500 $12.68 2,000 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Employee Stock Option (right to buy) Disposition 2017-07-10 3,500 $0.00 3,500 $1.89
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
16,725 2024-10-22 No 4 M Direct
Footnotes
  1. Includes 2,000 shares acquired by the Reporting Person under the Issuer's 2016 Employee Stock Purchase Plan on March 9, 2017.
  2. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 6, 2017.
  3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.36 to $12.84. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
  4. The option vests over a four-year period, with 1/4th of the shares subject to the option vesting on the one year anniversary of the vesting commencement date, and 1/36th of the remaining shares subject to the option vesting each month, subject to the Reporting Person continuing to be a service provider of the Issuer through each such date.